Vergelijking

Humanin vs. Pasireotid

Twee peptiden naast elkaar — identiteit, bewijsbasis, juridische status en bekende bijwerkingen.

Identiteit

Categorie

Onderzoek (overig)

CAS-nr.

330936-69-1

396091-73-9

Molecuulmassa

2687.27 g/mol

1047.21 g/mol

Halfwaardetijd

geen gegevens

Sequentie

Met-Ala-Pro-Arg-Gly-Phe-Ser-Cys-Leu-Leu-Leu-Leu-Thr-Ser-Glu-Ile-Asp-Leu-Pro-Val-Lys-Arg-Arg-Ala

geen gegevens

Werkingsmechanisme

Humanin

Humanin arises from a short open reading frame within the 16S rRNA region of the mitochondrial genome (MT-RNR2) — it is therefore not encoded by nuclear DNA. Mechanistically, preclinical work describes a cytoprotective, anti-apoptotic effect via multiple pathways: an extracellular interaction with a trimeric receptor complex of gp130, CNTFR and WSX-1 with downstream activation of JAK2/STAT3 signalling, as well as intracellular interactions including inhibition of the pro-apoptotic protein BAX (and of tBID), binding to IGFBP-3 with modulation of the IGF-1 axis, and interaction with FPRL1/FPRL2 receptors. These models derive predominantly from cell culture and rodents; the extent to which they reflect human physiology after administration of exogenous synthetic humanin is not established by controlled human trials.

Pasireotid

Pasireotide binds more broadly than older somatostatin analogs (SSTR1/2/3/5) with particularly high affinity for SSTR5. This suppresses, among others, ACTH release in Cushing's disease and GH release in acromegaly.

Bewijsbasis

Hoogste bewijs

Humane studie

Humane RCT

Studies

waarvan bij mensen

Geregistreerde effecten

Openstaande tegenstrijdigheden

Gedocumenteerde bijwerkingen

Juridische status

Country	Humanin	Pasireotid
Duitsland	Niet goedgekeurd	Op recept
Verenigde Staten	Alleen onderzoek	Op recept

Volledige vermeldingen

Humanin

Volledige vermelding →

Pasireotid

Volledige vermelding →

Frequently asked questions

What is the difference between Humanin and Pasireotid?: Humanin is classified as "Onderzoek (overig)", while Pasireotid is classified as "Onderzoek (overig)". Humanin: Humanin is a 24-amino-acid mitochondrial-encoded peptide (mitochondrial-derived peptide, MDP) whose open reading frame lies within the 16S rRNA region (gene MT-RNR2) of mitochondrial DNA. It is considered the founding member of the MDP family and was discovered in 2001 by the Hashimoto/Nishimoto group while searching for neuroprotective factors in the brain of an Alzheimer's patient. In basic research (including the laboratory of Pinchas Cohen) humanin is described as a cytoprotective, anti-apoptotic peptide and is studied in the contexts of Alzheimer's/neuroprotection, metabolism/insulin action and aging. The evidence comes almost entirely from cell and animal models and from observations of endogenous levels in humans; controlled human trials of exogenous humanin as a therapeutic are lacking. It is not approved as a medicine anywhere and is traded on the grey market as a research chemical. Pasireotid: Pasireotide is a multireceptor somatostatin analog binding to four of the five somatostatin receptors (especially SSTR5). It is approved for Cushing's disease and acromegaly. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Humanin or Pasireotid?: The highest available evidence level is "Humane studie" for Humanin and "Humane RCT" for Pasireotid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Humanin and Pasireotid in Germany and the United States?: Duitsland: Humanin — Niet goedgekeurd, Pasireotid — Op recept. Verenigde Staten: Humanin — Alleen onderzoek, Pasireotid — Op recept. These are factual summaries with source and review date on the individual pages.

Country

Humanin

Pasireotid

Duitsland

Niet goedgekeurd

Op recept

Verenigde Staten

Alleen onderzoek

Op recept

Frequently asked questions

What is the difference between Humanin and Pasireotid?

Humanin is classified as "Onderzoek (overig)", while Pasireotid is classified as "Onderzoek (overig)". Humanin: Humanin is a 24-amino-acid mitochondrial-encoded peptide (mitochondrial-derived peptide, MDP) whose open reading frame lies within the 16S rRNA region (gene MT-RNR2) of mitochondrial DNA. It is considered the founding member of the MDP family and was discovered in 2001 by the Hashimoto/Nishimoto group while searching for neuroprotective factors in the brain of an Alzheimer's patient. In basic research (including the laboratory of Pinchas Cohen) humanin is described as a cytoprotective, anti-apoptotic peptide and is studied in the contexts of Alzheimer's/neuroprotection, metabolism/insulin action and aging. The evidence comes almost entirely from cell and animal models and from observations of endogenous levels in humans; controlled human trials of exogenous humanin as a therapeutic are lacking. It is not approved as a medicine anywhere and is traded on the grey market as a research chemical. Pasireotid: Pasireotide is a multireceptor somatostatin analog binding to four of the five somatostatin receptors (especially SSTR5). It is approved for Cushing's disease and acromegaly. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Humanin or Pasireotid?

The highest available evidence level is "Humane studie" for Humanin and "Humane RCT" for Pasireotid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Humanin and Pasireotid in Germany and the United States?

Duitsland: Humanin — Niet goedgekeurd, Pasireotid — Op recept. Verenigde Staten: Humanin — Alleen onderzoek, Pasireotid — Op recept. These are factual summaries with source and review date on the individual pages.